

Possible cause for psoriasis discovered – Absence of a molecule causes psoriasis-like symptoms in mice

Psoriasis is an inflammatory skin condition that is very common in the Western world. Teams of researchers headed by Professor Michael Boutros at the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) and the Medical Faculty Mannheim of Heidelberg University have now discovered that an absence of the so-called “Wnt signaling pathway” causes a skin condition resembling psoriasis in mice. This cellular pathway involving molecular signals also plays an important part in tumor growth.

Two million people in Germany suffer from psoriasis. Those who are affected suffer from dry, sensitive and scaly skin. This complex condition involves a combination of a genetic predisposition to the disease, environmental factors, and an imbalance of the immune system. As a result, over the long term the skin loses its function as a natural barrier against pathogens, chemical and physical irritants leading to inflammations, autoimmune reactions, and infections.

In their present article, Professor Michael Boutros and Dr. Iris Augustin have looked into the communication between the outer layer of the skin (epidermis) and the immune system, focusing on a biochemical network within the cell called the “Wnt signaling pathway.” “Wnt signaling plays an important role during embryonic development in humans and animals, and is also involved in controlling the development of stem cells in the skin and gut,” Boutros says. Skin cells produce Wnt molecules, which have to be secreted in order to transmit crucial signals between cells. For this to happen, Wnt molecules are transported from the cell interior to its membrane; they are released from the cell with the aid of a cargo protein called Evi. Outside, Wnt binds to neighboring cells and triggers new signals. These lead, for example, to the production of new chemical messengers within the neighbors or the promotion of their growth.

In the current study, the researchers used mice whose cells are unable to produce Evi. In the absence of this cargo protein, Wnt molecules were unable to leave the cell of origin and trigger signals in neighbors. The researchers observed that the mice developed symptoms resembling those of psoriasis: “The skin gets inflamed, new vessels are formed, and epidermal cells multiply strongly and take on a scaly appearance,” Iris Augustin says. Additionally, the skin of these mice contained less than normal quantities of so-called “dendritic epidermal T cells” (DETCs).

“DETCs are immune cells in the skin that normally fend off invaders and prevent inflammation by slowing down immune cell infiltration from the bloodstream,” Augustin explains. “The absence of DETCs in the mouse skin probably prompts more immune cells to leave the bloodstream and infiltrate the skin.”

A comparison of the mouse model with tissue sections of psoriasis patients revealed clear parallels: Levels of the Evi cargo protein were also low in humans, and also resulted in weaker than normal Wnt signaling. “This suggests that the Wnt signaling pathway also plays an important role in human psoriasis,” Augustin says. “Our finding offers a new approach to understanding the complex processes that underlie inflammatory skin conditions.”

For a long time scientists have known that alterations in the Wnt pathway are also involved in the development of cancer. Higher than normal Wnt levels are linked, for example, to breast

cancer and colorectal cancer. The Wnt signal also seems to play an important part in glioblastoma, a type of human brain cancer. Last year, researchers in Michael Boutros' group found increased levels of Evi in glioblastoma cells. "This probably leads to stronger Wnt signals," Augustin says, "and it might explain our observation that these cancer cells grow more rapidly." Next the scientists will try to find out whether blocking Evi – and thus the Wnt signaling pathway – is an effective strategy to stop the growth of tumors.

Augustin I, Gross J, Baumann D, Korn C, Kerr G, Grigoryan T, Mauch C, Birchmeier W and Boutros M: Loss of epidermal Evi/Wls results in a phenotype resembling psoriasiform dermatitis. *The Journal of Experimental Medicine* 2013 Aug, DOI: 10.1084/jem.20121871.

A picture for this press release is available on the Internet at:

www.dkfz.de/de/presse/pressemitteilungen/2013/images/gewebeschnitt-PM-boutros.jpg

Caption:

Tissue sections: Mouse with healthy skin (left) and with skin symptoms resembling psoriasis (right).

The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) with its more than 2,500 employees is the largest biomedical research institute in Germany. At DKFZ, more than 1,000 scientists investigate how cancer develops, identify cancer risk factors and endeavor to find new strategies to prevent people from getting cancer. They develop novel approaches to make tumor diagnosis more precise and treatment of cancer patients more successful. The staff of the Cancer Information Service (KID) offers information about the widespread disease of cancer for patients, their families, and the general public. Jointly with Heidelberg University Hospital, DKFZ has established the National Center for Tumor Diseases (NCT) Heidelberg, where promising approaches from cancer research are translated into the clinic. In the German Consortium for Translational Cancer Research (DKTK), one of six German Centers for Health Research, DKFZ maintains translational centers at seven university partnering sites. Combining excellent university hospitals with high-profile research at a Helmholtz Center is an important contribution to improving the chances of cancer patients. DKFZ is a member of the Helmholtz Association of National Research Centers, with ninety percent of its funding coming from the German Federal Ministry of Education and Research and the remaining ten percent from the State of Baden-Württemberg.

Dr. Stefanie Seltmann
Leiterin Presse- und Öffentlichkeitsarbeit
Deutsches Krebsforschungszentrum
Im Neuenheimer Feld 280
D-69120 Heidelberg
T: +49 6221 42 2854
F: +49 6221 42 2968
presse@dkfz.de

Dr. Sibylle Kohlstädt
Presse- und Öffentlichkeitsarbeit
Deutsches Krebsforschungszentrum
Im Neuenheimer Feld 280
D-69120 Heidelberg
T: +49 6221 42 2843
F: +49 6221 42 2968
presse@dkfz.de